Abortion, InducedNCT00382538
Mifepristone and Mid-Trimester Termination of Pregnancy
A study testing Addition of mifepristone 200 mg 24 hours before induction in people with Abortion, Induced and Abortion, Second Trimester, run by Boston University at 1 site in United States.
Trial summary
Mid-second trimester medical terminations of pregnancy require admission to the hospital for the length of time it takes a woman to abort. The current protocol at BMC uses intra-amniotic digoxin injection the day prior to admission. Read more about this study
- Who is it for?
- Ages 16 to 45 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Abortion, Induced, Abortion, Second Trimester
- What is being tested?
- Addition of mifepristone 200 mg 24 hours before induction
- How many people
- 64 participants
- Where
- 1 siteUnited States
- Study dates
- Mar 2005to Nov 2006
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 45 years
- Women only
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- 16 years of age or over
- able to give informed consent in English or Spanish
- Requesting termination of pregnancy
Who cannot join
- Under 16 years of age
- rupture membranes or intrauterine death
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized, Placebo-Controlled, Double-Blinded Study of Mifepristone in Midtrimester Termination of Pregnancy
Mid-second trimester medical terminations of pregnancy require admission to the hospital for the length of time it takes a woman to abort. The current protocol at BMC uses intra-amniotic digoxin injection the day prior to admission. The following day, the woman is admitted and given sequential doses of misoprostol until delivery occurs. The average length of time between the first dose of misoprostol and delivery is 12 hours, requiring most women to stay overnight. This is a randomized, placebo-controlled, double-blinded study designed to determine whether adding mifepristone significantly reduces the induction interval time (time between starting the first misoprostol and delivery) required for a second trimester termination.
Read the detailed description
This is a randomized, placebo-controlled, double-blinded study.
Allocation Method: Women will be randomized using a computer-run random number table. Tablets will be placed in capsules by the pharmacy according to the randomization chart.
Blinding: Subjects will receive a capsule containing either 200 mg of mifepristone or 250 mg Vitamin C. Neither she nor the researcher will be aware of which medication she receives.
Outcomes: The primary outcome measured will be the mean interval from first misoprostol dose to fetal expulsion. Secondary outcomes include the proportion of women delivering within 24 hours from the first dose of misoprostol and the proportion of women with a complete delivery not requiring additional treatment for retained placenta. We will also compare the amount of pain medication used, as well as the length of hospital stay between the two groups.
Inclusion criteria Inclusion criteria: · Need for second trimester induction for termination of pregnancy · Gestational age of 18-23 weeks · At least 18 years of age or 16 years old with parental consent No medical contraindication to the use of digoxin and misoprostol for the purposes of inducing abortion. · Able and willing to give informed consent in English or Spanish
Exclusion criteria Exclusion criteria: · Known allergy to mifepristone, misoprostol or prostaglandins · Pre-existing intrauterine fetal demise · Premature preterm rupture of membranes · IUD in place · History of chronic adrenal failure, porphyrias; or concurrent long-term corticosteroid treatment Unable or unwilling to give informed consent in English or Spanish
Involvement in the study will be as follows: on study day number one, all patients undergo an ultrasound-guided amniocentesis with intra-amniotic injection of digoxin regardless of entry into the study. Study patients will be randomized to the treatment or placebo group, and will receive one of two similar-looking tablets containing the allocated medication. The tablet will be swallowed in the clinic. The patient, researchers and the care providers will be blinded to group assignment. All patients return to the hospital the the day after their digoxin injection for induction. From this point on, the treatment of women enrolled and those not enrolled in the study will be identical; they are admitted to the hospital and induction for termination is begun using an initial 400mcg of misoprostol buccally. The initial dose is followed by 200 mcg of misoprostol every six hours until delivery is successful or 24 hours passes without delivery. Less than 5% of women require more than 24 hours of induction, and approximately 15% require extraction of the placenta if it does not pass spontaneously after the fetus. The subjects enrolled will not differ from other termination patients in regards to the following: 1. the number of appointments or time required in the hospital 2. use of intra-amniotic digoxin 3. termination method; misoprostol, 400 mg, followed by 200 mg every 6 hours 4. pain medication administration (PCA narcotics) 5. Medical evaluation of need to use other methods of completing abortion if 24 hours has elapsed after first misoprostol dose without delivery.
Analytic Plan:
The primary outcome is the length of induction interval for termination. The Kaplan-Meier procedure will be utilized to create a survival curve for analysis of induction to delivery interval by time. Demographic data for each group will also be compared to assure that there are no other differences between groups. Chi -square analysis will be used for dichotomous variables and t-tests for continuous variables.Study Size and Power:
A power calculation was performed for time from induction to delivery using a significant value of 0.05 and power of 80% using a survival analysis power formula. We used our previous data to estimate the mean time of induction and then estimated a likely delta (difference between the two treatment groups) of 35%. The number of patients needed in each group using this calculation is 32, and therefore the total number needed is 64.
- Conditions
- Abortion, Induced, Abortion, Second Trimester
- Being tested
- Addition of mifepristone 200 mg 24 hours before induction
- Keywords
- mifepristone, induction, abortion, injection, intra-amniotic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Addition of mifepristone 200 mg 24 hours before inductionDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
Time from start of induction to fetal delivery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2006 (estimated)
- Study startMar 2005
- Primary completionNov 2006
- Study completionNov 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Abortion, InducedStudies of the same condition, open and under way.
- More trials run by Boston UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Enrolment
- 64 participants
Sponsor and investigators
- Lead sponsor
- Boston University
- Sponsor type
- University, hospital or other
- Investigators
- Lynn Borgatta, MD, MPH, Principal investigator, Boston University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00382538
- Sponsor's protocol ID
- 24597
- Status last verified
- Oct 2008
- First submitted
- 28 Sep 2006
- Last updated
- 7 Oct 2008
- Results posted
- No
Publications
Kapp N, Borgatta L, Stubblefield P, Vragovic O, Moreno N. Mifepristone in second-trimester medical abortion: a randomized controlled trial. Obstet Gynecol. 2007 Dec;110(6):1304-10. doi: 10.1097/01.AOG.0000289577.32274.a5.
PubMed 18055725
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Placebo-Controlled, Double-Blinded Study of Mifepristone in Midtrimester Termination of Pregnancy
- ClinicalTrials.gov ID
- NCT00382538
- Acronym / sponsor ID
- 24597
- Conditions
- Abortion, Induced, Abortion, Second Trimester
- Keywords
- mifepristone, induction, abortion, injection, intra-amniotic
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 64 participants
- Lead sponsor
- Boston UniversityUniversity, hospital or other
- Study start
- Mar 2005
- Primary completion
- Nov 2006 (actual)
- Study completion
- Nov 2006 (actual)
- First posted
- 29 Sep 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Mid-second trimester medical terminations of pregnancy require admission to the hospital for the length of time it takes a woman to abort. The current protocol at BMC uses intra-amniotic digoxin injection the day prior to admission. The following day, the woman is admitted and given sequential doses of misoprostol until delivery occurs. The average length of time between the first dose of misoprostol and delivery is 12 hours, requiring most women to stay overnight. This is a randomized, placebo-controlled, double-blinded study designed to determine whether adding mifepristone significantly reduces the induction interval time (time between starting the first misoprostol and delivery) required for a second trimester termination.
Detailed description
This is a randomized, placebo-controlled, double-blinded study.
Allocation Method: Women will be randomized using a computer-run random number table. Tablets will be placed in capsules by the pharmacy according to the randomization chart.
Blinding: Subjects will receive a capsule containing either 200 mg of mifepristone or 250 mg Vitamin C. Neither she nor the researcher will be aware of which medication she receives.
Outcomes: The primary outcome measured will be the mean interval from first misoprostol dose to fetal expulsion. Secondary outcomes include the proportion of women delivering within 24 hours from the first dose of misoprostol and the proportion of women with a complete delivery not requiring additional treatment for retained placenta. We will also compare the amount of pain medication used, as well as the length of hospital stay between the two groups.
Inclusion criteria Inclusion criteria: · Need for second trimester induction for termination of pregnancy · Gestational age of 18-23 weeks · At least 18 years of age or 16 years old with parental consent No medical contraindication to the use of digoxin and misoprostol for the purposes of inducing abortion. · Able and willing to give informed consent in English or Spanish
Exclusion criteria Exclusion criteria: · Known allergy to mifepristone, misoprostol or prostaglandins · Pre-existing intrauterine fetal demise · Premature preterm rupture of membranes · IUD in place · History of chronic adrenal failure, porphyrias; or concurrent long-term corticosteroid treatment Unable or unwilling to give informed consent in English or Spanish
Involvement in the study will be as follows: on study day number one, all patients undergo an ultrasound-guided amniocentesis with intra-amniotic injection of digoxin regardless of entry into the study. Study patients will be randomized to the treatment or placebo group, and will receive one of two similar-looking tablets containing the allocated medication. The tablet will be swallowed in the clinic. The patient, researchers and the care providers will be blinded to group assignment. All patients return to the hospital the the day after their digoxin injection for induction. From this point on, the treatment of women enrolled and those not enrolled in the study will be identical; they are admitted to the hospital and induction for termination is begun using an initial 400mcg of misoprostol buccally. The initial dose is followed by 200 mcg of misoprostol every six hours until delivery is successful or 24 hours passes without delivery. Less than 5% of women require more than 24 hours of induction, and approximately 15% require extraction of the placenta if it does not pass spontaneously after the fetus. The subjects enrolled will not differ from other termination patients in regards to the following: 1. the number of appointments or time required in the hospital 2. use of intra-amniotic digoxin 3. termination method; misoprostol, 400 mg, followed by 200 mg every 6 hours 4. pain medication administration (PCA narcotics) 5. Medical evaluation of need to use other methods of completing abortion if 24 hours has elapsed after first misoprostol dose without delivery.
Analytic Plan:
The primary outcome is the length of induction interval for termination. The Kaplan-Meier procedure will be utilized to create a survival curve for analysis of induction to delivery interval by time. Demographic data for each group will also be compared to assure that there are no other differences between groups. Chi -square analysis will be used for dichotomous variables and t-tests for continuous variables.Study Size and Power:
A power calculation was performed for time from induction to delivery using a significant value of 0.05 and power of 80% using a survival analysis power formula. We used our previous data to estimate the mean time of induction and then estimated a likely delta (difference between the two treatment groups) of 35%. The number of patients needed in each group using this calculation is 32, and therefore the total number needed is 64.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
Who may qualify
- Ages
- 16 to 45 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (3 listed)
- 16 years of age or over
- able to give informed consent in English or Spanish
- Requesting termination of pregnancy
Key exclusion criteria (2 listed)
- Under 16 years of age
- rupture membranes or intrauterine death
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Addition of mifepristone 200 mg 24 hours before induction | Drug | – |
Primary outcome
Time from start of induction to fetal delivery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2008.
- Derived from this study: PubMed 18055725Kapp N, Borgatta L, Stubblefield P, Vragovic O, Moreno N. Mifepristone in second-trimester medical abortion: a randomized controlled trial. Obstet Gynecol. 2007 Dec;110(6):1304-10. doi: 10.1097/01.AOG.0000289577.32274.a5.
Related trials for Abortion, Induced
Not yet recruitingObservational study
Cervical Length Reference Range at 28-34 Weeks in Singleton Pregnancies
Preterm Birth, Cervical Length
Not yet recruiting
Virtual Reality for Pain and Anxiety During Surgical Uterine Evacuation After Early Pregnancy Loss
Early Pregnancy Loss, Procedural Pain
Active, not recruitingObservational study
Factors Influencing Fertility or Pregnancy Health
Menstrual Cycles, Conception
Not yet recruitingPhase 3
Efficacy of Progesterone and Low Molecular Weight Heparin in Recurrent Pregnancy Loss
Pregnancy Loss, Pregnancy Loss, Early
Not yet recruitingPhase 4
Azithromycin for Cerclage Prophylaxis
Cervical Insufficiency
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lynn Borgatta, MD, MPH principal investigator
Boston University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Addition of mifepristone 200 mg 24 hours before induction in people with Abortion, Induced and Abortion, Second Trimester, run by Boston University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Oct 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time from start of induction to fetal delivery. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00382538, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2008.